Skip to main content
Top
Published in: BMC Nephrology 1/2024

Open Access 01-12-2024 | Human Immunodeficiency Virus | Research

The clinical utility of cystatin C based eGFR in assessing renal function among HIV/AIDs patients on ART at Mildmay Uganda

Authors: Enock Wekiya, Godfrey P. Mujuzi, Jane Nakiyingi, Juliet Sanya, Moses Matovu, Ocung Guido, Jane Nakaweesi, Charles Karamagi, Joan K. Nakayaga, Edrisa I. Mutebi, Damalie Nakanjako

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

Background

In clinical practice, Measurement of estimated glomerular filtration rates (eGFR) is the gold standard assessing renal function the glomerular filtration rate often estimated from plasma creatinine. Several studies have shown Cystatin C based eGFR (Cys C) to be a better parameter for the diagnosis of impaired renal function. Cystatin C based eGFR has been proposed as a potential renal function marker but its use in HIV&AIDS patients has not been well evaluated.

Methods

A cross sectional study was carried out on 914 HIV&AIDS patients on antiretroviral therapy (ART) attending Mildmay Uganda for care and treatment between January to March 2015. Serum Cystatin C based eGFR was measured using the particle enhanced immunoturbidimetric assay. Creatinine was analyzed using enzymatic Creatinine PAP method and creatinine clearance was calculated according to C&G.

Results

The sensitivity of Cystatin C based eGFR was 15.1% (95% CI = 8.4, 24) with specificity 99.3% (95% CI = 98- 99.7). The positive and negative predictive values were 70.0% (95% CI 45.7–88.1) and 91.2% (95% CI 98.11–92.94) respectively. The positive likelihood ratio was 18.81 and negative likelihood ratio was 0.85. Cystatin C based eGFR had diagnostic accuracy of 90.7 and area under curve was 0.768.

Conclusion

Cystatin C based eGFR exhibited a high specificity and a high positive likelihood ratio in diagnosis of kidney disease among HIV&AIDS patients. Cystatin C based eGFR can be used as a confirmatory test.
Literature
2.
go back to reference Broder S, Gallo RC. A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med. 1984;311(20):1292–7.CrossRefPubMed Broder S, Gallo RC. A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med. 1984;311(20):1292–7.CrossRefPubMed
9.
go back to reference Izzedine H, Launay-Vacher V, Deray G. Antiviral Drug-Induced Nephrotoxicity. Am J Kidney Dis. 2005;45(5):804–17.CrossRefPubMed Izzedine H, Launay-Vacher V, Deray G. Antiviral Drug-Induced Nephrotoxicity. Am J Kidney Dis. 2005;45(5):804–17.CrossRefPubMed
10.
go back to reference Jones R, Scott C, Nelson M, Levy J. Renal complications in HIV. Int J Clin Pract. 2007;61(6):991–8.CrossRefPubMed Jones R, Scott C, Nelson M, Levy J. Renal complications in HIV. Int J Clin Pract. 2007;61(6):991–8.CrossRefPubMed
12.
go back to reference Cohen AH, Sun NC, Shapshak P, Imagawa DT. Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod Pathol. 1989;2(2):125–8.PubMed Cohen AH, Sun NC, Shapshak P, Imagawa DT. Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod Pathol. 1989;2(2):125–8.PubMed
13.
go back to reference Valeri A, Neusy AJ. Acute and chronic renal disease in hospitalized AIDS patients. Clin Nephrol. 1991;35(3):110–8.PubMed Valeri A, Neusy AJ. Acute and chronic renal disease in hospitalized AIDS patients. Clin Nephrol. 1991;35(3):110–8.PubMed
15.
go back to reference Rao TKS, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med. 1987;316(17):1062–8.CrossRefPubMed Rao TKS, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med. 1987;316(17):1062–8.CrossRefPubMed
16.
go back to reference Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–82.CrossRefPubMed Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–82.CrossRefPubMed
19.
go back to reference Baumgarten M, Gehr T. Chronic kidney disease: detection and evaluation. Am Fam Physician. 2011;84(10):1138–48.PubMed Baumgarten M, Gehr T. Chronic kidney disease: detection and evaluation. Am Fam Physician. 2011;84(10):1138–48.PubMed
21.
go back to reference Jo JY, Ryu SA, Kim JI, Lee EH, Choi IC. Comparison of five glomerular filtration rate estimating equations as predictors of acute kidney injury after cardiovascular surgery. Sci Rep. 2019;9(1):11072.CrossRefPubMedPubMedCentral Jo JY, Ryu SA, Kim JI, Lee EH, Choi IC. Comparison of five glomerular filtration rate estimating equations as predictors of acute kidney injury after cardiovascular surgery. Sci Rep. 2019;9(1):11072.CrossRefPubMedPubMedCentral
25.
go back to reference Grubb A, Björk J, Lindström V, Sterner G, Bondesson P, Nyman U. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. Scand J Clin Lab Invest. 2005;65(2):153–62.CrossRefPubMed Grubb A, Björk J, Lindström V, Sterner G, Bondesson P, Nyman U. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. Scand J Clin Lab Invest. 2005;65(2):153–62.CrossRefPubMed
26.
go back to reference Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A. Cystatin C as a marker of GFR—history, indications, and future research. Clin Biochem. 2005;38(1):1–8.CrossRefPubMed Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A. Cystatin C as a marker of GFR—history, indications, and future research. Clin Biochem. 2005;38(1):1–8.CrossRefPubMed
27.
go back to reference Donadio C, Lucchesi A, Ardini M, Giordani R, Cystatin C. β2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal. 2001;24(5):835–42.CrossRefPubMed Donadio C, Lucchesi A, Ardini M, Giordani R, Cystatin C. β2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal. 2001;24(5):835–42.CrossRefPubMed
28.
go back to reference Reed CH. Diagnostic applications of cystatin C. Br J Biomed Sci. 2000;57(4):323–9.PubMed Reed CH. Diagnostic applications of cystatin C. Br J Biomed Sci. 2000;57(4):323–9.PubMed
29.
go back to reference Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48(5):699–707.CrossRefPubMed Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48(5):699–707.CrossRefPubMed
30.
go back to reference Horio M, Orita Y, Manabe S, Sakata M, Fukunaga M. Formula and nomogram for predicting creatinine clearance from serum creatinine concentration. Clin Exp Nephrol. 1997;1(2):110–4.CrossRef Horio M, Orita Y, Manabe S, Sakata M, Fukunaga M. Formula and nomogram for predicting creatinine clearance from serum creatinine concentration. Clin Exp Nephrol. 1997;1(2):110–4.CrossRef
31.
go back to reference Chaparro AI, Mitchell CD, Abitbol CL, Wilkinson JD, Baldarrago G, Lopez E, et al. Proteinuria in children infected with the human immunodeficiency virus. J Pediatr. 2008;152(6):844–9.CrossRefPubMed Chaparro AI, Mitchell CD, Abitbol CL, Wilkinson JD, Baldarrago G, Lopez E, et al. Proteinuria in children infected with the human immunodeficiency virus. J Pediatr. 2008;152(6):844–9.CrossRefPubMed
32.
go back to reference Eke FU, Anochie IC, Okpere AN, et al. Proteinuria in HIV positive children a pilot study. Pediatr Nephrol. 2007;22:1456. Eke FU, Anochie IC, Okpere AN, et al. Proteinuria in HIV positive children a pilot study. Pediatr Nephrol. 2007;22:1456.
33.
go back to reference Wools-Kaloustian KK, Gupta SK. Will there be an epidemic of HIV-related chronic kidney disease in sub-Saharan Africa? Too soon to tell. Kidney Int. 2008;74(7):845–7.CrossRefPubMed Wools-Kaloustian KK, Gupta SK. Will there be an epidemic of HIV-related chronic kidney disease in sub-Saharan Africa? Too soon to tell. Kidney Int. 2008;74(7):845–7.CrossRefPubMed
35.
go back to reference Kalyesubula R, Lunyera J, Makanga G, Kirenga B, Amukele TK. A 4-year survey of the spectrum of renal disease at a National Referral Hospital Outpatient Clinic in Uganda. Kidney Int. 2015;87(3):663.CrossRefPubMed Kalyesubula R, Lunyera J, Makanga G, Kirenga B, Amukele TK. A 4-year survey of the spectrum of renal disease at a National Referral Hospital Outpatient Clinic in Uganda. Kidney Int. 2015;87(3):663.CrossRefPubMed
36.
go back to reference Chantrel F, Agin A, Offner M, Koehl C, Moulin B, Hannedouche T. Comparison of cystatin C versus creatinine for detection of mild renal failure. Clin Nephrol. 2000;54(5):374–81.PubMed Chantrel F, Agin A, Offner M, Koehl C, Moulin B, Hannedouche T. Comparison of cystatin C versus creatinine for detection of mild renal failure. Clin Nephrol. 2000;54(5):374–81.PubMed
37.
go back to reference Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum Cystatin C as an endogenous marker of renal function in patients with chronic kidney disease. Ren Fail. 2008;30(2):181–6.CrossRefPubMed Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum Cystatin C as an endogenous marker of renal function in patients with chronic kidney disease. Ren Fail. 2008;30(2):181–6.CrossRefPubMed
38.
go back to reference Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. The Lancet. 1998;352(9130):783–4.CrossRef Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. The Lancet. 1998;352(9130):783–4.CrossRef
39.
go back to reference Leventhal JS, Ross MJ. Pathogenesis of HIV-Associated Nephropathy. Semin Nephrol. 2008;28(6):523–34.CrossRefPubMed Leventhal JS, Ross MJ. Pathogenesis of HIV-Associated Nephropathy. Semin Nephrol. 2008;28(6):523–34.CrossRefPubMed
40.
go back to reference Eneyew K, Seifu D, Amogne W, Menon MKC. Assessment of Renal Function among HIV-Infected Patients on Combination Antiretroviral Therapy at Tikur Anbessa Specialized Hospital, Addis Ababa. Ethiopia Technol Invest. 2016;7(3):107–22.CrossRef Eneyew K, Seifu D, Amogne W, Menon MKC. Assessment of Renal Function among HIV-Infected Patients on Combination Antiretroviral Therapy at Tikur Anbessa Specialized Hospital, Addis Ababa. Ethiopia Technol Invest. 2016;7(3):107–22.CrossRef
41.
go back to reference Marras D, Bruggeman LA, Gao F, Tanji N, Mansukhani MM, Cara A, et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med. 2002;8(5):522–6.CrossRefPubMed Marras D, Bruggeman LA, Gao F, Tanji N, Mansukhani MM, Cara A, et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med. 2002;8(5):522–6.CrossRefPubMed
42.
go back to reference Bruggeman LA, Ross MD, Tanji N, Cara A, Dikman S, Gordon RE, et al. Renal Epithelium Is a Previously Unrecognized Site of HIV-1 Infection. J Am Soc Nephrol. 2000;11(11):2079.CrossRefPubMed Bruggeman LA, Ross MD, Tanji N, Cara A, Dikman S, Gordon RE, et al. Renal Epithelium Is a Previously Unrecognized Site of HIV-1 Infection. J Am Soc Nephrol. 2000;11(11):2079.CrossRefPubMed
44.
go back to reference Yilma D, Abdissa A, Kæstel P, Tesfaye M, Olsen MF, Girma T, et al. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir. BMC Infect Dis. 2020;20(1):582.CrossRefPubMedPubMedCentral Yilma D, Abdissa A, Kæstel P, Tesfaye M, Olsen MF, Girma T, et al. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir. BMC Infect Dis. 2020;20(1):582.CrossRefPubMedPubMedCentral
Metadata
Title
The clinical utility of cystatin C based eGFR in assessing renal function among HIV/AIDs patients on ART at Mildmay Uganda
Authors
Enock Wekiya
Godfrey P. Mujuzi
Jane Nakiyingi
Juliet Sanya
Moses Matovu
Ocung Guido
Jane Nakaweesi
Charles Karamagi
Joan K. Nakayaga
Edrisa I. Mutebi
Damalie Nakanjako
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-024-03581-3

Other articles of this Issue 1/2024

BMC Nephrology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.